Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Appointed director
Notes underwriting agrmnt
|
|
Allarity Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/27/2023 |
8-K
| Resignation/termination of a director, Appointed a new director |
| 09/26/2022 |
8-K
| Appointed a new director|
Docs:
|
"Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors Cambridge, MA U.S.A. — Allarity Therapeutics, Inc. , a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, today announced the appointment of Jerry McLaughlin as a new member of its Board of Directors, effective October 1, 2022. Mr. McLaughlin is a highly accomplished biotechnology executive with extensive experience in financing, drug development, licensing, commercialization, and product lifecycle management. Mr. McLaughlin is expected to serve on the compensation, and audit committees as an independent director. “I am delighted that Jerry has chosen to join Allarity’ s board at ...",
"UPDATE TO COMPANY OVERVIEW PRESENTATION" |
|
|
|